Immunotherapy before targeted therapy improves survival in advanced melanoma
Researchers reported a 20 percent advantage in the two-year overall survival rate for subjects with advanced melanoma and a mutation in the BRAF gene, specifically a BRAF V600 mutation, who were initially… read more.